Pfizer (PFE) Resumen de Acciones
Pfizer Inc. descubre, desarrolla, fabrica, comercializa, distribuye y vende productos biofarmacéuticos en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 2/6 |
| Dividendos | 4/6 |
Recompensas
Análisis de riesgos
PFE Community Fair Values
Create NarrativeSee what 911 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Pharmaceuticals & Biotech opportunity
LO
Fair Value from
US$7.674.9% infravalorado descuento intrínseco
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.
Read full narrativeCompetidores de Pfizer Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$26.53 |
| Máximo en las últimas 52 semanas | US$28.75 |
| Mínimo de 52 semanas | US$21.97 |
| Beta | 0.31 |
| Cambio en 1 mes | -4.67% |
| Variación en 3 meses | 0.15% |
| Cambio de 1 año | 16.41% |
| Variación en 3 años | -30.73% |
| Variación en 5 años | -33.16% |
| Variación desde la OPV | 5,754.91% |
Noticias y actualizaciones recientes
Recent updates
Actualización del análisis • May 03
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post Settlement Outlook
Pfizer's updated analyst price target has shifted slightly lower to $24.00 from $25.00 as analysts factor in a steeper projected revenue decline, a modestly higher profit margin outlook, and mixed views on the post-settlement pipeline and patent overhang. Analyst Commentary Recent research on Pfizer highlights a split view.Seeking Alpha • May 01
Pfizer: Why You Should Double Down Into Q1
Summary Pfizer remains a high-conviction, undervalued Strong Buy with a robust pipeline and aggressive growth in oncology and obesity platforms. PFE's 2026 guidance reaffirmation is the key near-term catalyst, with management targeting $59.5–$62.5B revenue and $2.8–$3 EPS despite patent expirations. Onshoring high-margin production and aggressive cost-cutting are central to de-risking LOE headwinds and expanding operating margins through 2027. At 8.13x P/E and a 6.4% dividend yield, PFE offers compelling value versus peers, with risks around patent cliffs and obesity platform execution. Read the full article on Seeking Alpha
Actualización del análisis • Apr 19
PFE: GLP-1 And Oncology Advancements Will Support Post LOE Repricing
Pfizer's analyst fair value estimate has been adjusted modestly higher to $35.96 from $35.33, as analysts factor in recent price target raises and mixed views on the post-2028 pipeline, loss of exclusivity risks, and evolving expectations for the GLP-1 and oncology portfolios. Analyst Commentary Recent Street research on Pfizer reflects a split view, with some firms expressing caution around patent expiries and near term visibility, while other bullish analysts focus on the potential in GLP-1 and oncology programs, along with broader sector appeal in healthcare.Actualización del análisis • Apr 05
PFE: Obesity And Oncology Pipeline Progress Will Drive Post LOE Rerating
Analysts have nudged Pfizer's implied fair value modestly higher to about $35.33 per share, citing recent price target increases of around $1 to $3 and research that highlights contributions from its GLP-1, oncology, and hematology pipelines, while also noting the long-term patent cliff and revenue uncertainty. Analyst Commentary Recent research on Pfizer shows a split view, with some firms highlighting long term headwinds from loss of exclusivity while others point to pipeline depth and business development as potential offsets.Actualización del análisis • Mar 22
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Post 2028 Outlook
Pfizer's updated analyst narrative keeps fair value steady at $25.00, with recent Street research showing price targets clustering from $25.00 to $35.00 as analysts weigh concerns about a post-2028 patent cliff against interest in the GLP-1, oncology, and collaboration pipelines, as well as healthcare's perceived appeal in a riskier macro backdrop. Analyst Commentary Recent Street research around Pfizer reflects a split view, with some firms pointing to potential in GLP-1, oncology, hematology, and collaborations, while others emphasize the scale and timing of the expected revenue cliff and limited visibility on offsets.Actualización del análisis • Mar 08
PFE: Patent Cliff And GLP 1 Pipeline Will Shape Next Decade
Analysts lifted their fair value estimate for Pfizer from $23.00 to $25.00 per share, reflecting updated views that weigh a stronger GLP 1 and oncology pipeline against ongoing concerns about the patent cliff and near term revenue visibility. Analyst Commentary Recent Street research on Pfizer presents a mixed picture, with more cautious voices focusing on patent expirations, limited near term pipeline visibility, and questions around how quickly new therapies can support growth.Actualización del análisis • Feb 21
PFE: Obesity Pipeline Progress Will Drive Post LOE Re Rating
Pfizer's updated analyst price target edges lower to about $35 per share. This reflects analysts' focus on ongoing losses of exclusivity, a slightly softer revenue and margin outlook, and tempered expectations for future P/E as some firms initiate or assume coverage with more cautious views around the next few years.Actualización del análisis • Feb 07
PFE: Obesity Pipeline And LOE Headwinds Will Shape Future Re Rating
Narrative Update Analysts have trimmed their fair value estimate for Pfizer from $36.16 to $35.46, reflecting more cautious assumptions on revenue trends and profit margins, even as some on the Street highlight new assets and deals that they believe could support a higher future P/E multiple. Analyst Commentary Recent Street research on Pfizer highlights a mix of caution and optimism, with several firms reassessing how the pipeline and recent deals might offset upcoming patent expiries and support the valuation over time.Actualización del análisis • Jan 24
PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares
Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.Actualización del análisis • Jan 10
PFE: Obesity Deal And LOE Overhang Will Shape Re Rating Potential
Analysts have trimmed their price expectations for Pfizer, citing ongoing revenue uncertainty around an expected US$15b to US$20b loss of exclusivity over the next few years, even as some see support from the obesity deal and a broader positive stance on large cap biopharma. Analyst Commentary Recent research highlights a split view on Pfizer, with some caution around the expected US$15b to US$20b loss of exclusivity over the next few years and others pointing to potential upside linked to obesity treatments and a broader positive stance on large cap biopharma.Artículo de análisis • Jan 08
Pfizer (NYSE:PFE) Has Announced A Dividend Of $0.43
Pfizer Inc. ( NYSE:PFE ) will pay a dividend of $0.43 on the 6th of March. This makes the dividend yield 6.8%, which...Actualización del análisis • Dec 25
PFE: Obesity Bid And Margin Outlook May Drive Re-Rating Ahead
Analysts have nudged their price target on Pfizer higher by $2 to $30, citing improving margin expectations and a more constructive sector backdrop, despite tempered revenue growth assumptions. Analyst Commentary Bullish analysts highlight that the latest price target increase reinforces a gradually improving sentiment toward Pfizer, with investors starting to look past the near term revenue slowdown and focus more on medium term cash flow durability and pipeline execution.Artículo de análisis • Dec 18
Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.43
The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March...
Actualización del análisis • Dec 11
PFE: Obesity Pipeline Expansion Will Drive Upside Amid Sector Rerating
Analysts nudged their price target on Pfizer higher to $30 from $28, citing a sector wide rerating on benign U.S. drug pricing developments and the strategic upside from an expanded obesity pipeline and broader large cap biopharma innovation. Analyst Commentary Bullish analysts highlight that Pfizer is benefiting from a constructive shift in U.S. drug pricing expectations and a broader rerating of large cap biopharma, which supports the recent price target increase and stabilizes valuation multiples.Actualización del análisis • Nov 13
PFE: Obesity Deal Will Drive Upside After Sector Underperformance And Portfolio Shifts
Pfizer’s analyst price target was raised from $28 to $30 per share, reflecting a modest increase in fair value. Analysts cite sector-wide re-rating and updated fundamentals, including acquisition activity and anticipated drug pipeline developments, as key drivers for the revision.Artículo de análisis • Aug 12
Solid Earnings Reflect Pfizer's (NYSE:PFE) Strength As A Business
NYSE:PFE 1 Year Share Price vs Fair Value Explore Pfizer's Fair Values from the Community and select yours Pfizer...Seeking Alpha • Apr 30
Pfizer's Q1 Update May Mark A Bottom In The Stock
Summary Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again. PFE stock is trading at trough valuations and at a larger-than-usual discount vs peers. So I think there is some decent margin of safety. Technical analysis vs SPX500 suggests PFE may be forming a bottom, but strong buyer signals are still absent. Read the full article on Seeking AlphaSeeking Alpha • Apr 23
Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Summary Pfizer Inc.'s stock has performed poorly despite massive COVID-19 earnings, trading at a 12-year low due to flawed M&A deals and high debt levels. The discontinuation of danuglipron, a potential obesity drug, highlights Pfizer's struggle to develop successful new drugs, impacting its market position. Pfizer faces significant challenges including patent expiries, drug pricing controls, and questionable management decisions, casting doubt on its future performance. Despite these issues, Pfizer's high dividend yield and substantial revenue generation provide some investor appeal, but I maintain a "Hold" rating ahead of Q1 earnings. Read the full article on Seeking AlphaRentabilidad de los accionistas
| PFE | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 1.0% | 6.2% | 3.2% |
| 1Y | 16.4% | 33.4% | 31.0% |
Rentabilidad vs. Industria: Los resultados de PFE fueron inferiores a los de la industria US Pharmaceuticals, que obtuvo un rendimiento del 33.4% el año pasado.
Rentabilidad vs. Mercado: PFE obtuvo unos resultados inferiores a los del mercado US, que fueron del 31% el año pasado.
Volatilidad de los precios
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: PFE no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de PFE (3%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1849 | 75,000 | Albert Bourla | www.pfizer.com |
Pfizer Inc. descubre, desarrolla, fabrica, comercializa, distribuye y vende productos biofarmacéuticos en Estados Unidos y a escala internacional. Opera en tres segmentos: Biopharma, PC1 y Pfizer Ignite. La empresa ofrece productos de medicina interna, incluidos productos para enfermedades metabólicas cardiovasculares bajo la marca Eliquis; productos para la migraña bajo las marcas Nurtec ODT/Vydura y Zavzpret; vacunas bajo las marcas Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac y Trumenba; y Paxlovid para el tratamiento de la COVID-19.
Resumen de fundamentos de Pfizer Inc.
| Estadísticas fundamentales de PFE | |
|---|---|
| Capitalización bursátil | US$150.75b |
| Beneficios(TTM) | US$7.48b |
| Ingresos (TTM) | US$63.32b |
20.2x
Ratio precio-beneficio (PE)2.4x
Ratio precio-ventas (PS)¿Está PFE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PFE | |
|---|---|
| Ingresos | US$63.32b |
| Coste de los ingresos | US$15.96b |
| Beneficio bruto | US$47.36b |
| Otros gastos | US$39.88b |
| Beneficios | US$7.48b |
Últimos beneficios comunicados
Mar 29, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 1.31 |
| Margen bruto | 74.80% |
| Margen de beneficio neto | 11.81% |
| Ratio deuda/patrimonio | 71.6% |
¿Cómo se ha desempeñado PFE a largo plazo?
Ver rendimiento histórico y comparativaDividendos
6.5%
Rentabilidad actual por dividendo131%
Ratio de pagos¿Paga PFE dividendos fiables?
Ver historial de dividendos e índices de referencia de PFE| fechas de dividendos de Pfizer | |
|---|---|
| Fecha ex dividendo | May 08 2026 |
| Fecha de pago de dividendos | Jun 12 2026 |
| Días hasta ex dividendo | 1 day |
| Días hasta la fecha de pago de dividendos | 36 days |
¿Paga PFE dividendos fiables?
Ver historial de dividendos e índices de referencia de PFEAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/06 09:29 |
| Precio de las acciones al final del día | 2026/05/06 00:00 |
| Beneficios | 2026/03/29 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Pfizer Inc. está cubierta por 44 analistas. 26 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |